Clear Search

Showing 2 result for “Zhu D”.

June 2022

X線学的異常を有するまたは有しない体軸性脊椎炎におけるイキセキズマブへの52週時反応性に関する性別ごとのベースライン特徴: フェーズ3無作為化対照試験結果

Advance Therapy,2022 Jun;39(6):2806-2819.−022−02132−2

van der Horst-Bruinsma et al., carried out a post-hoc analysis to confirm that the clinical presentations and responses to ixekizumab therapy may differ in male and female patients.


May 2022

乾癬性関節炎におけるイキセキズマブの安全性: Data 4臨床試験からの2000人年超の曝露データ

doi: 10.1136/annrheumdis-2021-222027

This analysis aimed to report the safety profile of ixekizumab for the PsA SPIRIT programme. The overall safety profile and tolerability of ixekizumab are consistent with the previously known safety profile in patients with PsA.